Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 57 results
Filters: First Letter Of Title is R  [Clear All Filters]
Found 57 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

R

Shiboski CH, Chen H, Ghannoum MA, et al. "Role of oral candidiasis in TB and HIV co-infection: AIDS Clinical Trial Group Protocol A5253." Int. J. Tuberc. Lung Dis.. 2014;18(6):682-8.
Boltz VF, Zheng Y, Lockman S, et al. "Role of low-frequency HIV-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapine." Proc. Natl. Acad. Sci. U.S.A.. 2011;108(22):9202-7.
Shikuma CM, Gangcuangco LMar A, Killebrew DA, et al. "The role of HIV and monocytes/macrophages in adipose tissue biology." J. Acquir. Immune Defic. Syndr.. 2014;65(2):151-9.
Kang M, Chung RT. "The role of early viral decline in the treatment of hepatitis C in HIV-1-coinfected persons." J. Acquir. Immune Defic. Syndr.. 2007;46(3):371-3.
Messer K, Vaida F, Hogan C. "Robust analysis of biomarker data with informative missingness using a two-stage hypothesis test in an HIV treatment interruption trial: AIEDRP AIN503/ACTG A5217." Contemp Clin Trials. 2006;27(6):506-17.
Bisson GP, Ramchandani R, Miyahara S, et al. "Risk factors for early mortality on antiretroviral therapy in advanced HIV-infected adults." AIDS. 2017;31(16):2217-2225.
Grant PM, Komarow L, Andersen J, et al. "Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection." PLoS ONE. 2010;5(7):e11416.
Tenorio AR, Chan ES, Bosch RJ, et al. "Rifaximin has a marginal impact on microbial translocation, T-cell activation and inflammation in HIV-positive immune non-responders to antiretroviral therapy - ACTG A5286." J. Infect. Dis.. 2015;211(5):780-90.
Clark SA, Shulman NS, Bosch RJ, Mellors JW. "Reverse transcriptase mutations 118I, 208Y, and 215Y cause HIV-1 hypersusceptibility to non-nucleoside reverse transcriptase inhibitors." AIDS. 2006;20(7):981-4.
Su Z, Gulick RM, Krambrink A, et al. "Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211." J. Infect. Dis.. 2009;200(11):1724-8.
Gandhi RT, Bosch RJ, Aga E, et al. "Residual plasma viraemia and infectious HIV-1 recovery from resting memory CD4 cells in patients on antiretroviral therapy: results from ACTG A5173." Antivir. Ther. (Lond.). 2013;18(4):607-13.
Yang Y, Degruttola V. "Resampling-based methods in single and multiple testing for equality of covariance/correlation matrices." Int J Biostat. 2012;8(1):Article 13.
Foulkes AS, DeGruttola VG. "A resampling-based approach to multiple testing with uncertainty in phase." Int J Biostat. 2007;3(1):Article 2.
Skowron G, Spritzler JG, Weidler J, et al. "Replication capacity in relation to immunologic and virologic outcomes in HIV-1-infected treatment-naive subjects." J. Acquir. Immune Defic. Syndr.. 2009;50(3):250-8.
Mwafongo A, Nkanaunena K, Zheng Y, et al. "Renal events among women treated with tenofovir/emtricitabine in combination with either lopinavir/ritonavir or nevirapine." AIDS. 2014;28(8):1135-42.
F Romo T, Smeaton LM, Campbell TB, et al. "Renal and metabolic toxicities following initiation of HIV-1 treatment regimen in a diverse, multinational setting: a focused safety analysis of ACTG PEARLS (A5175)." HIV Clin Trials. 2014;15(6):246-60.
Paul RH, Ernst T, Brickman AM, et al. "Relative sensitivity of magnetic resonance spectroscopy and quantitative magnetic resonance imaging to cognitive function among nondemented individuals infected with HIV." J Int Neuropsychol Soc. 2008;14(5):725-33.
Graham CS, Wells A, Liu T, et al. "Relationships between cellular immune responses and treatment outcomes with interferon and ribavirin in HIV/hepatitis C virus co-infection." AIDS. 2006;20(3):345-51.
Li JZ, Heisey A, Ahmed H, et al. "Relationship of HIV reservoir characteristics with immune status and viral rebound kinetics in an HIV therapeutic vaccine study." AIDS. 2014;28(18):2649-57.
Wilkin TJ, Ribaudo HR, Tenorio AR, Gulick RM. "The relationship of CCR5 antagonists to CD4+ T-cell gain: a meta-regression of recent clinical trials in treatment-experienced HIV-infected patients." HIV Clin Trials. 2010;11(6):351-8.
Luetkemeyer AF, Rosenkranz SL, Lu D, et al. "Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study." Clin. Infect. Dis.. 2013;57(4):586-93.
Li JZ, Paredes R, Ribaudo HJ, et al. "Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure." AIDS. 2012;26(2):185-92.
Blodget E, Shen C, Aldrovandi G, et al. "Relationship between microbial translocation and endothelial function in HIV infected patients." PLoS ONE. 2012;7(8):e42624.
Smurzynski M, Wu K, Benson CA, Bosch RJ, Collier AC, Koletar SL. "Relationship between CD4+ T-cell counts/HIV-1 RNA plasma viral load and AIDS-defining events among persons followed in the ACTG longitudinal linked randomized trials study." J. Acquir. Immune Defic. Syndr.. 2010;55(1):117-27.
Weinberg A, Bosch R, Bennett K, et al. "Regulatory T cells and the risk of CMV end-organ disease in patients with AIDS." J. Acquir. Immune Defic. Syndr.. 2014;66(1):25-32.
Wilkin TJ, McKinnon JE, A DiRienzo G, et al. "Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes." J. Infect. Dis.. 2009;199(6):866-71.
Swindells S, A DiRienzo G, Wilkin T, et al. "Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression." JAMA. 2006;296(7):806-14.
Tashima KT, Mollan KR, Na L, et al. "Regimen selection in the OPTIONS trial of HIV salvage therapy: drug resistance, prior therapy, and race-ethnicity determine the degree of regimen complexity." HIV Clin Trials. 2015;16(4):147-56.
Longenecker CT, Kitch D, Sax PE, et al. "Reductions in Plasma Cystatin C After Initiation of Antiretroviral Therapy Are Associated With Reductions in Inflammation: ACTG A5224s." J. Acquir. Immune Defic. Syndr.. 2015;69(2):168-77.
Kendall MA, Andersen JW, van der Horst C. "A reduced frequency visit schedule underreports adverse events that resulted in dose modifications or treatment discontinuations in HIV/AIDS clinical trials: ACTG DACS 207." Contemp Clin Trials. 2006;27(3):287-94.

Pages